Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype

PURPOSE: To determine the long-term prognosis in each phenotypic subset of breast cancer related to residual cancer burden (RCB) after neoadjuvant chemotherapy alone, or with concurrent human epidermal growth factor receptor 2 (HER2)–targeted treatment. METHODS: We conducted a pathologic review to m...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Symmans, W. Fraser, Wei, Caimiao, Gould, Rebekah, Yu, Xian, Zhang, Ya, Liu, Mei, Walls, Andrew, Bousamra, Alex, Ramineni, Maheshwari, Sinn, Bruno, Hunt, Kelly, Buchholz, Thomas A., Valero, Vicente, Buzdar, Aman U., Yang, Wei, Brewster, Abenaa M., Moulder, Stacy, Pusztai, Lajos, Hatzis, Christos, Hortobagyi, Gabriel N.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2017
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5455352/
https://ncbi.nlm.nih.gov/pubmed/28135148
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.63.1010
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars